Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.07 USD
Change Today -0.0003 / -0.40%
Volume 14.0K
ULGX On Other Exchanges
As of 11:49 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

urologix inc (ULGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $0.17
52 Week Low
08/24/15 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UROLOGIX INC (ULGX)

Related News

No related news articles were found.

urologix inc (ULGX) Related Businessweek News

No Related Businessweek News Found

urologix inc (ULGX) Details

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy urethral tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate and destroys prostate tissue that reduces constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

61 Employees
Last Reported Date: 09/19/14
Founded in 1991

urologix inc (ULGX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $200.0K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

urologix inc (ULGX) Key Developments

Urologix, Inc. expected to report Fiscal Year 2015 results on September 2, 2015. This event was calculated by Capital IQ (Created on August 27, 2015).

Urologix, Inc. expected to report Fiscal Year 2015 results on September 2, 2015. This event was calculated by Capital IQ (Created on August 27, 2015).

Urologix Announces Its Decision To Terminate And Suspend The Registration Of Its Stock With SEC

Urologix, Inc. announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the "SEC"). The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace. The Company intends to file a Form 15 with the SEC to voluntarily deregister its common stock and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on or about July 10, 2015. As a result of the filing of the Form 15, the Company's obligation to file certain Exchange Act reports and forms with the SEC, including Forms 10-K, 10-Q, and 8-K, will cease. Other filing requirements will terminate upon the effectiveness of the deregistration, which is expected to occur 90 days after the filing of the Form 15. The Company's board of directors decided to deregister and terminate Exchange Act reporting after careful consideration of the advantages and disadvantages of being an SEC reporting company. The Company's board of directors considered many factors in making this decision, including the following: the costs, both direct and indirect, associated with the preparation and filing periodic reports with the SEC, including the continually escalating costs and burdens associated with complying with recent legislation applicable to reporting companies such as the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; the additional demands placed on management and Company personnel to comply with requirements required of registrants; the historically low stock price of the Company's common stock; the nature and extent of the trading in the Company's common stock; the current level of analyst coverage and minimal liquidity for the Company's common stock; and the value of an SEC-registered entity to potential strategic partners.

Urologix Conducting A Strategic Review

Urologix, Inc. (OTCPK:ULGX) will continue reviewing various strategic alternatives available to the Company, including the sale of the Company or its assets, partnering or other collaboration agreements, or a merger, reverse merger or other strategic transaction.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULGX:US $0.07 USD -0.0003

ULGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.30 USD +0.21
Cogentix Medical Inc $1.55 USD -0.02
Medifocus Inc C$0.05 CAD -0.005
Olympus Corp ¥4,115 JPY -60.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ULGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROLOGIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at